Showing results (11-20 of 42) with videos related to
Sort By:
Pageof 5
Clinical Pharmacokinetics|September 9, 2018
A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4Michel Tod, S Goutelle, N Bleyzac, et al.Annales Pharmaceutiques Francaises|July 10, 2004
[Busulfan and cycosporin in bone graft children]V Bertolle, P Martin, N Bleyzac, et al.The AAPS Journal|December 8, 2016
A Model for Predicting the Interindividual Variability of Drug-Drug InteractionsM Tod, L Bourguignon, N Bleyzac, et al.Therapie|September 1, 2000
[Can we use a Bayesian method to build a pharmacokinetic population in two steps?]D Cabelguenne, N Bleyzac, C Pivot, et al.Journal of Chromatography. B, Biomedical Sciences and Applications|March 10, 2001
New sensitive assay of vancomycin in human plasma using high-performance liquid chromatography and electrochemical detectionP Favetta, J Guitto, N Bleyzac, et al.Therapie|May 1, 1997
[Non-parametric estimation of pharmacokinetic parameters of amikacin in patients with non-insulin-dependent diabetes mellitus]S Corvaisier, N Bleyzac, M A Confesson, et al.Therapeutic Drug Monitoring|April 5, 2021
Impact of a Bayesian Individualization of Cyclosporine Dosage Regimen for Children Undergoing Allogeneic Hematopoietic Cell Transplantation: A Cost-Effectiveness AnalysisC Beyron, A Ceraulo, Y Bertrand, et al.Medecine Et Maladies Infectieuses|November 20, 2010
[Assessment of adherence to Afssaps guidelines for the prescription of antifungals in pediatric hemato-oncology]A Berthe, A Duclos, I Ray-coquard, et al.Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|August 16, 2014
[Lacidipine efficacy and safety for high blood pressure treatment in pediatric oncohematology]E Bernard, V Mialou, A Dony, et al.Therapeutic Drug Monitoring|June 13, 2000
Diurnal changes in the pharmacokinetic behavior of amikacinN Bleyzac, B Allard-Latour, A Laffont, et al.Pageof 5